OC
EVFM

Oppenheimer & Co’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Oppenheimer & Co’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,235
Closed -$81K – 1514
2020
Q4 		$81K Sell
2,235
-1,049
-32% -$37.9K ﹤0.01% 1314
2020
Q3 		$116K Sell
3,284
-2,493
-43% -$108K ﹤0.01% 1222
2020
Q2 		$245K Buy
5,777
+3,717
+180% +$251K 0.01% 1041
2020
Q1 		$164K Buy
+2,060
New +$165K 0.01% 1063

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
GLA
Great Lakes Advisors Chicago, Illinois $12.1B AUM 29.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co's EVFM Position: Q1 2021 in Review

Oppenheimer & Co sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q1 2021, closing a stake of 2,235 shares — an estimated $81K sold.

Oppenheimer & Co first reported a position in EVFM in Q1 2020 and held it in 4 quarters. The position peaked at $245K in Q2 2020. 103 funds tracked by Wall St. Rank hold EVFM as of Q1 2021.

  • Oppenheimer & Co reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 2,235 Evofem Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $81K.
  • Oppenheimer & Co first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2020 and held it in 4 quarters.
  • Oppenheimer & Co's Evofem Biosciences, Inc. Common Stock position peaked at $245K in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q1 2021.

Based on Oppenheimer & Co's 13F filing for Q1 2021, filed 10 May 2021.